INTRODUCTION
Discontinuation of imatinib (Glivec/Gleevec, STI571; Novartis, Summit, NJ) is currently an investigational approach for patients with chronic-phase chronic myelogenous leukemia (CML) in prolonged complete molecular response (CMR). In 2007, we reported a pilot study to evaluate the feasibility and safety of imatinib discontinuation in patients in CMR Ͼ 2 years and observed that half of the patients experienced molecular relapse during the 6 months after treatment discontinuation. 1 No late molecular relapses were observed in the remaining patients, with an extended follow-up Ͼ 4 years. These results were confirmed in the multicenter STIM (Stop Imatinib) study. 2 The initial analysis reported the results of 69 patients with 12-month follow-up. Forty-two patients (61%) lost CMR, including 40 within the first 6 months. At 12 months, the probability of persistent CMR was 41%. These results were confirmed in more patients, with longer follow-up, 3 as well as in three independent studies. [4] [5] [6] Molecular relapse in the STIM study was defined as positivity of BCR-ABL transcripts with quantitative reverse transcriptase polymerase chain
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T reaction QRT-PCR with a ratio of BCR-ABL to ABL Ն 10
Ϫ5 confirmed by a second successive analysis indicating an increase in relation to the first analysis. However, during the molecular follow-up of patients included in the pilot and STIM studies, we observed occasional positivity of BCR-ABL transcript levels, suggesting that the definition for molecular relapse could be revised. We thus evaluated whether the loss of major molecular response (MMR; defined as Յ 0.1% BCR-ABL IS ) was a safe and clinically relevant measure for defining molecular relapse after imatinib discontinuation. Here we present the results of the multicenter observational study A-STIM (According to STIM) to evaluate the persistence of MMR in patients with CML who had previously stopped imatinib after prolonged CMR.
PATIENTS AND METHODS

Patients
Criteria for registration in the A-STIM study were the same as those described for the STIM study, 2 with the exception that patients with confirmed CMR with occasional weekly positive samples before study entry were also considered eligible. Other therapies before imatinib were allowed, with the exception of allogeneic hematopoietic stem-cell transplantation. Molecular assessments before inclusion were performed in local laboratories participating in the French network of quality control for BCR-ABL quantification (Groupe des Biologistes Moléculaires des Hémopathies Malignes [GBMHM]).
7 All patients agreed to be registered in this observational study after receiving written information. The study was approved by the Comité Consultatif sur le Traitement de l'Information en Matière de Recherche dans le Domaine de la Santé (CCTIRS) and Commission Nationale de l'Informatique et des Libertés (CNIL) French ethics committees.
Study Evaluations
CMR was defined as undetectable BCR-ABL transcript with sensitivity Ն 40,000 amplified copies of the ABL control gene, in accordance with the level of sensitivity routinely applied within laboratories participating in the French GBMHM network. Confirmed CMR (cCMR) was defined as two consecutive samples with no detectable transcripts; stable cCMR was defined as no sample with detectable transcripts; unstable cCMR was defined as cCMR with unconfirmed occasional positive samples (Ͻ level of 0.1% BCR-ABL IS ) during the CMR follow-up period (minimum assessment frequency of every 6 months).
Molecular biology follow-up included quantification of BCR-ABL transcripts with QRT-PCR from peripheral blood, performed every month in the first year after imatinib discontinuation and every 2 months from the second year onward. After 2 years, molecular biology follow-up was recommended every 3 months. Molecular relapse was defined as loss of MMR (Ͼ 0.1% BCR-ABL IS ). Loss of CMR was defined by identification of BCR-ABL transcripts during follow-up after discontinuation according to the criteria described in the STIM study.
2 In the event of loss of MMR, reintroduction of imatinib was recommended.
Cell Sorting
Peripheral blood mononuclear and polymorphonuclear granulocytes were isolated by high-density gradient Ficoll centrifugation (Lymphocytepoly; Cedarlane, Burlington, Ontario, Canada). Cells were washed twice in phosphate-buffered saline (PBS) and resuspended in 1% fetal calf serum (FCS) in PBS. The cellular fraction was incubated for 30 minutes at 4°C with selected monoclonal antibodies for single-or five-color membrane staining. The following antibodies were used: PerCP-Cy5.5-conjugated anti-CD45 (clone 2D1; Becton Dickinson, Franklin Lakes, NJ), Pacific Blue-conjugated anti-CD3 (clone SP34; Becton Dickinson), PE-Cy7-conjugated anti CD20 (clone L27, Becton Dickinson), PE-conjugated anti-CD15 (clone HI98; Becton Dickinson), and FITC-conjugated anti-CD14 (clone M0P9; Becton Dickinson). For all analyses, isotype control antibodies were used in parallel. Cell subset populations were sorted with a BD ARIA I FACS machine equipped with Diva software (Becton Dickinson).
In Vitro Hematopoietic Progenitor and Stem-Cell Assays
Bone marrow samples from two patients were tested for the detection of BCR-ABL mRNA on individual and/or pooled hematopoietic colonies generated by clonogenic and long-term culture-initiating cell (LTC-IC) assays as previously reported.
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Statistical Methods
Relapse-free survival (RFS) was measured from date of imatinib discontinuation to date of molecular relapse or date of the last molecular evaluation for nonrelapsing patients. Incidence of molecular relapse was estimated with the cumulative incidence function accounting for competing events and was calculated for all patients losing MMR. Patients were also analyzed using the STIM definition for relapse. Treatment-free remission (TFR) was defined as the time between the date of imatinib cessation to the date of restarting imatinib for any reason or, if imatinib was not restarted, the date of last contact. TFR was estimated using the Kaplan-Meier method. Values of interest are presented with 95% CIs. RFS was also estimated in patients with cCMR and persistent CMR and in patients with cCMR with occasional positive samples (Ͻ level of 0.1% BCR-ABL IS ) before study entry. Potential prognostic factors for MMR loss such as age, sex, Sokal risk group, prior interferon (IFN) alfa therapy, duration of imatinib therapy, time to CMR, and CMR duration until imatinib discontinuation were analyzed among all patients. XLSTAT software (version 2012.2.02 (Addinsoft, New York, NY) and R software (R Foundation for Statistical Computing, Vienna, Austria) were used.
RESULTS
Patient Characteristics
A total of 80 patients with CML were registered in the A-STIM study between June 2006 and June 2012. Patient characteristics are summarized in Table 1 . Prior therapy before imatinib included IFN in 42 patients (52%) and cytarabine alone in one patient. Fifteen patients received combined therapy (imatinib and pegylated IFN [n ϭ 8] or imatinib and cytarabine [n ϭ 7]). Median time from imatinib initiation to discontinuation was 79 months (range, 30 to 145 months). Median duration of CMR was 41 months (range, 24 to 96 months). Forty-two patients (52%) were classified as having unstable cCMR before study entry.
Molecular Relapse
Median follow-up after imatinib discontinuation was 31 months (range, 8 to 92 months), including 76 patients with follow-up Ն 12 months. A summary of patients with molecular relapse is provided in Table 2 . Twenty-nine patients (36%) lost MMR. Median time off therapy for these patients was 4 months (range, 2 to 17 months), and only four patients (14%) lost MMR after 6 months off therapy (at 7, 7, 11, and 17 months). Cumulative incidence of MMR loss was estimated as 35% (95% CI, 25% to 46%) at 12 months and 36% (95% CI, 26% to 47%) at 24 months ( Fig 1A, solid line) . Therapy was restarted in two patients before losing MMR, resulting in competing risks in the cumulative incidence analysis. TFR was estimated as 64% (95% CI, 54% to 75%) at 12 and 24 months and 61% (95% CI, 51% to 73%) at 36 months ( Fig 1B) .
We also analyzed molecular relapse according to loss of CMR as defined in the STIM study. The corresponding rate of molecular relapse was 56% (45 patients) after a median time off therapy of 4 months (range, 1 to 40 months). Of note, eight (18%) of the 45 patients lost CMR after 6 months, including two late molecular relapses at months 35 and 40. Cumulative incidence of CMR loss using the STIM definition was 51% (95% CI, 41% to 63%) at 12 months and 54% (95% CI, 44% to 66%) at 24 months ( Fig 1A, dashed line) . We looked at the agreement between the two methods of evaluation (Table 2) . Sixteen patients who did not lose MMR were consequently considered as relapsing using the STIM criteria only. As a result, cumulative incidence of MMR loss in patients who lost CMR according to the STIM criteria was estimated as 62% (95% CI, 48% to 75%) at 12 months and 65% (95% CI, 51% to 78%) at 24 months ( Fig 1C) .
Fluctuation of BCR-ABL Positivity
Fifty-one patients remained in MMR after imatinib discontinuation; 28 (55%) had BCR-ABL transcript positivity. Positivity corresponded to either occasional positive assessments of BCR-ABL transcripts Ͻ the MMR threshold in 12 patients (24%) or to Ն two consecutive positive values Ͻ the MMR threshold in 16 patients (31%; Table 2 ). This latter situation was selected to define BCR-ABL fluctuation. An example is presented in Figure 2A for a representative patient without loss of MMR after imatinib discontinuation with follow-up Ͼ 5 years. We performed cell sorting of peripheral blood mononuclear cells and polymorphonuclear granulocytes from three patients with fluctuating values of BCR-ABL transcripts after imatinib discontinuation. After normalization according to ABL expression, BCR-ABL signal was mostly detectable in the CD15ϩ cell fraction (Fig 2B) .
Clonogenic Assays in Patients With Fluctuating BCR-ABL Levels in Peripheral Blood
In two patients with fluctuating BCR-ABL positivity, we performed colony-forming unit in culture (CFU-C) and LTC-IC assays using bone marrow-derived CD34ϩ cells to detect BCR-ABLexpressing clonogenic and more primitive hematopoietic stem cells; 1,000 and 2,000 CD34ϩ cells (representing 1/11th and 1/230th of the CD34ϩ cells, respectively) were plated in CFU-C assays, generating a mean number of 42 and 143 CFU-Cs per dish, respectively. QRT-PCR analysis for BCR-ABL was performed in 20 individual and 10 pools of 10 CFU-Cs in one patient (allowing screening of 120 CFU-Cs total) and in 40 individual CFU-Cs in the second patient. In the latter patient, 40 individual LTC-IC-derived CFU-Cs were analyzed. BCR-ABL expression was not detectable in either CFU-C or LTC-IC. At the time of stem-cell analyses, both patients were still receiving imatinib therapy; they stopped the treatment after bone marrow aspirate was performed. In those two patients, fluctuating BCR-ABL positivity in peripheral blood was detected 3 and 5 months after discontinuation of imatinib, respectively.
Factors Influencing Loss of MMR
A nonsignificant trend was observed for a lower CI of MMR loss by 24 months in patients previously treated with IFN as compared with patients treated with first-line imatinib (28.8% v 44.7%; P ϭ .061). With the limitation of the sample size, no other potential prognostic factors analyzed had a significant impact on MMR duration, and none were identified as independent significant prognostic factors (Appendix Tables A1 to A3, online only). We also investigated if patients with unstable cCMR before study entry were at higher risk of losing MMR as compared with patients with stable cCMR. RFS curves were not statistically different (Fig 3A) . A nonsignificant trend was observed for shorter RFS in patients with unstable cCMR when loss of CMR (STIM criteria) was used to define molecular relapse (Fig 3B) .
Second CMR
Treatment was resumed in 31 patients after loss of MMR (imatinib [n ϭ 27], nilotinib [n ϭ 2], and dasatinib [n ϭ 1]). One additional patient refused to restart therapy and is currently being observed, with BCR-ABL IS Ͻ the 1% threshold. MMR was regained in all re-treated patients. Median follow-up after treatment resumption was 17 months (range, 2 to 83 months). Twenty-three patients regained CMR, and eight patients are in MMR while receiving therapy after Ն 2 to Ն 17 months. Cumulative incidence function (CIF) of molecular relapse and treatmentfree remission (TFR) after imatinib discontinuation in 80 patients with chronic myelogenous leukemia. (A) CIF according to major molecular response (MMR) loss and complete molecular response (CMR) loss using STIM (Stop Imatinib) study definition. Cumulative incidence of MMR loss was estimated as 35% (95% CI, 25% to 46%) at 12 months and 36% (95% CI, 26% to 47%) at 24 months, with plateau after 24 months. Cumulative incidence of molecular relapse using STIM definition was 51% (95% CI, 41% to 63%) at 12 months and 54% (95% CI, 44% to 66%) at 24 months. (B) Kaplan-Meier estimate of TFR after stopping imatinib. TFR was estimated as 64% (95% CI, 54% to 75%) at both 12 and 24 months and 61% (95% CI, 51% to 73%) at 36 months. (C) CIF according to subsequent MMR loss among 45 patients who lost CMR according to STIM criteria. Cumulative incidence of MMR loss after loss of CMR was 62% (95% CI, 48% to 75%) at 12 months and 65% (95% CI, 51% to 78%) at 24 months. 9 Cytarabine was discontinued after 12 months, and imatinib was maintained. Complete cytogenetic response was achieved at 6 months and major molecular response (MMR) at 12 months. BCR-ABL transcripts were undetectable in June 2004, and imatinib was discontinued in July 2006 after 2 years of complete molecular response. Long-term follow-up revealed fluctuations in BCR-ABL IS values without loss of MMR, with followup Ͼ 5 years without therapy. (B) Cell sorting in three patients with fluctuating BCR-ABL positivity. Cell-sorting fractions CD3ϩ, CD20ϩ, CD14ϩ, and CD15ϩ were evaluated for BCR-ABL expression. Cell-sorting purity was 98% for CD3ϩ, 93% for CD14ϩ, 99% for CD15ϩ, and 96% for CD20ϩ cell fractions. Results were normalized on cell number within each fraction and expressed as relative value by reference of signal detected in blood. BCR-ABL relative signal was predominantly detected in CD15ϩ fraction as compared with CD3ϩ, CD14ϩ, and CD20ϩ fractions. months (Fig 4) . No loss of hematologic response was observed during the discontinuation period.
BCR-ABL
Safety
No patient died during the follow-up period. One patient who started imatinib 10 years after CML diagnosis experienced lymphoid blast crisis 9 months after restarting imatinib while in MMR. This woman (age 33 years) was diagnosed with chronic-phase CML with low Sokal score in 1996. She obtained complete cytogenetic response after 6 months of IFN. IFN was interrupted in 1999 in CMR because of adverse effects. Imatinib was started in 2006 after a molecular relapse, and a second CMR was achieved in 2007. The patient was included in the A-STIM study in August 2009, and imatinib was stopped. CMR was lost 9 months later (BCR-ABL IS , 0.025%), and MMR was lost on the second assessment 1 month later (BCR-ABL IS , 0.14%). Imatinib (400 mg per day) was resumed in July 2010, and MMR was regained in October 2010 (BCR-ABL IS , 0.015%). Lymphoid blast crisis was diagnosed 8.5 months after restarting imatinib. There was no evidence of mutation; cytogenetic analysis showed a complex karyotype with major-route additional chromosomal aberrations, including der(22). Complete remission was achieved with the combination of nilotinib and chemotherapy (after failure of dasatinib and chemotherapy), and the patient underwent allogeneic matched unrelated-donor transplantation conditioned by total-body irradiation and cyclophosphamide in July 2011. The patient was alive at last follow-up.
DISCUSSION
Imatinib discontinuation offers a new perspective to patients with CML who are in prolonged CMR. We previously reported a multicenter study showing that 39% of patients were still in CMR without evidence of disease recurrence after discontinuing imatinib. 2 We now extend these observations by validating the loss of MMR as a practical criterion to decide to restart therapy. This choice was based on two observations: First, we found that some patients experienced BCR-ABL transcript fluctuations during the off-therapy period without progression as defined in the STIM study, 2 and second, we anticipated that it would be easier to define molecular relapse using the wellstandardized loss of MMR criterion. The results of our study reveal that 61% of patients are still in MMR long term after imatinib discontinuation. We also report that resuming imatinib after MMR loss is not associated with reduced probability of regaining CMR.
The safety of tyrosine kinase inhibitor (TKI) discontinuation is now supported by the results and the follow-up of at least four studies, including the STIM study, and no event of progression was described. [1] [2] [3] [4] [5] [6] We report here the first case, to our knowledge, of progression to blast crisis after a trial of imatinib cessation. None of the patient's characteristics marked her as high risk for a trial of cessation. This patient lost CMR (STIM study definition) and MMR at the same time point, and therefore, the restart of treatment was not delayed by the loss of MMR definition. MMR was regained after 3 months. Because sudden blast crisis occurring in responding patients with (A) Overall probability of maintaining MMR in patients with stable confirmed complete molecular response (cCMR; 38 patients) and unstable cCMR before study entry (42 patients) was estimated as 65% (95% CI, 47% to 78%) and 64% (95% CI, 48% to 77%) at 12 months, respectively (P ϭ .75). (B) Overall probability of maintaining CMR in patients with stable cCMR (39 patients) and unstable cCMR before study entry (42 patients) was estimated as 55% (95% CI, 38% to 69%) and 43% (95% CI, 28% to 57%) at 12 months, respectively (P ϭ .18).
CMR (%)
Time ( CML has already been reported in imatinib therapy, this event may not be formally related to imatinib discontinuation but deserves to be considered with caution in the follow-up of ongoing discontinuation trials.
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Previous studies used restrictive criteria to define CMR persistence in terms of duration and sensitivity (4.5-to 5-log).
2-6 These requirements were necessary in the setting of a proof-of-concept clinical trial such as the STIM study. However, in real life, the strict definition of stable cCMR is difficult to achieve. Milojkovic et al 11 defined cCMR as two consecutive samples with no detectable transcripts Ն 4 weeks apart with an ABL1 control Ͼ 40,000 copies. They estimated that 54 (10.3%) of 521 patients met the criteria for cCMR and only 10 patients (2%) met the strict criteria of stable cCMR to be eligible in a STIM-equivalent study. As an example, 52% of the patients included in the A-STIM study met the criteria for cCMR but experienced occasional BCR-ABL positivity (unstable cCMR). Those patients were not at higher risk of losing MMR as compared with patients with cCMR ( Fig 3A) . This observation may potentially increase by two-fold the number of patients eligible for TKI discontinuation. The proportion of patients eligible for a stop-imatinib approach may also depend on the definition of CMR, which will be clarified in the future by the standardization of the nomenclature.
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Our study was not adequately powered to identify parameters significantly associated with the CI of MMR loss. This may be partially explained by the lower number of events observed in the A-STIM study and also by the use of a different end point to define molecular relapse as compared with the STIM study. We found a trend for a lower risk of relapse in IFN-pretreated patients, as in other discontinuation studies. [4] [5] [6] Even in this highly selected population of complete responders, residual BCR-ABL-positive cells may persist. Chomel et al 8 conducted a pilot study evaluating the presence of BCR-ABL-expressing marrow leukemic stem cells in six patients with CML and sustained undetectable molecular residual disease induced by IFN or imatinib. BCR-ABL-expressing leukemic stem cells were detected in all patients tested. These results are in line with the detection of the BCR-ABL signal using PCR on DNA from patients with CMR. 4 In confirmation, we have observed repeated and significant positive values of BCR-ABL transcript levels in patients who discontinued imatinib. This pattern of molecular positivity has also been described in patients who stopped IFN alfa while in complete cytogenetic response and after allogeneic stem-cell transplantation. 13, 14 On the basis of our observations, we defined fluctuations in BCR-ABL transcripts as Ն two consecutive positive values Ͻ the MMR threshold during molecular follow-up after discontinuation, a phenomenon observed in 30% of our patients in MMR. Using cell sorting in three fluctuating patients from the A-STIM study, we were able to confirm that BCR-ABL signal was mostly present in the CD15ϩ fraction (Fig 2B) , demonstrating first that BCR-ABL residual signal was not related to long-living lymphoid cells and second that residual CML cells retain clonogenic potential. Interestingly, in two patients with fluctuating BCR-ABL levels, the analysis of marrow clonogenic cells and LTC-IC-derived clonogenic cells were negative for BCR-ABL at the time of treatment discontinuation, suggesting the persistence of highly quiescent stem cells undetectable by current stem-cell assays despite further production of BCR-ABL-expressing mature myeloid cells. These cells may amplify in the terminal stages of hematopoiesis and could then be detected by sorting the CD15ϩ cells in blood. Taken together, these results suggest that qualitative in addition to quantitative factors are involved in controlling CML stem cells after imatinib discontinuation.
In conclusion, our results show that the probability of losing MMR after imatinib discontinuation is estimated as 36% in the long term. MMR loss could be used as a practical criterion for future discontinuation studies. This criterion has been chosen for analysis in the EURO-SKI (Europe Stop TKI) trial, which is currently in progress. Abbreviations: CMR, complete molecular response; MMR, major molecular response.
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